
Amy Hauck Newman, Ph.D.
Senior Investigator
Molecular Targets and Medications Discovery Branch, Medicinal Chemistry Section
NIDA
Scientific Director
NIDA
Triad Technology Center
333 Cassell Drive
Room 3444
Baltimore, MD 21224
443-740-2887
Research Topics
Selected Publications
Newman AH, Beuming T, Banala AK, Donthamsetti P, Pongetti K, LaBounty A, Levy B, Cao J, Michino M, Luedtke RR, Javitch JA, Shi L. Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. J Med Chem. 2012;55(15):6689-99.
Loland CJ, Mereu M, Okunola OM, Cao J, Prisinzano TE, Mazier S, Kopajtic T, Shi L, Katz JL, Tanda G, Newman AH. R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse. Biol Psychiatry. 2012;72(5):405-13.
Kumar V, Bonifazi A, Ellenberger MP, Keck TM, Pommier E, Rais R, Slusher BS, Gardner E, You ZB, Xi ZX, Newman AH. Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment. J Med Chem. 2016;59(16):7634-50.
Bonifazi A, Yano H, Guerrero AM, Kumar V, Hoffman AF, Lupica CR, Shi L, Newman AH. Novel and Potent Dopamine D2 Receptor Go-Protein Biased Agonists. ACS Pharmacol Transl Sci. 2019;2(1):52-65.
Newman AH, Cao J, Keighron JD, Jordan CJ, Bi GH, Liang Y, Abramyan AM, Avelar AJ, Tschumi CW, Beckstead MJ, Shi L, Tanda G, Xi ZX. Translating the atypical dopamine uptake inhibitor hypothesis toward therapeutics for treatment of psychostimulant use disorders. Neuropsychopharmacology. 2019;44(8):1435-1444.
Related Scientific Focus Areas
Social and Behavioral Sciences
View additional Principal Investigators in Social and Behavioral Sciences
This page was last updated on November 2nd, 2018